Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

by Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati
Published 2021-01-01

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France

by Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze, Anne-Françoise Gaudin
Published 2020-09-01

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma

by Dirk Schadendorf, Mark Middleton, Jeffrey Weber, Delphine Hennicken, Paolo Ascierto, Andriy Moshyk, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati
Published 2020-11-01

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma

by Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O. Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M. Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill
Published 2022-03-01